Published in Cell Death Differ on January 01, 2003
Targeting of hepatitis C virus core protein to mitochondria through a novel C-terminal localization motif. J Virol (2004) 1.67
Hepatitis C virus core protein is a dimeric alpha-helical protein exhibiting membrane protein features. J Virol (2005) 1.34
Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition. PLoS One (2009) 1.33
Hepatitis C virus (HCV) proteins induce NADPH oxidase 4 expression in a transforming growth factor beta-dependent manner: a new contributor to HCV-induced oxidative stress. J Virol (2009) 1.27
E6AP ubiquitin ligase mediates ubiquitylation and degradation of hepatitis C virus core protein. J Virol (2006) 1.19
Viral RNA silencing suppressors (RSS): novel strategy of viruses to ablate the host RNA interference (RNAi) defense system. Virus Res (2010) 1.17
HCV genotype distribution and possible transmission risks in Lahore, Pakistan. World J Gastroenterol (2010) 1.14
Memory T-cell-mediated immune responses specific to an alternative core protein in hepatitis C virus infection. J Virol (2004) 1.14
Membrane binding properties and terminal residues of the mature hepatitis C virus capsid protein in insect cells. J Virol (2004) 1.08
Characterization of hepatitis C virus core protein multimerization and membrane envelopment: revelation of a cascade of core-membrane interactions. J Virol (2009) 1.01
Hepatitis C virus NS2 protein triggers endoplasmic reticulum stress and suppresses its own viral replication. J Hepatol (2010) 0.99
Analysis of hepatitis C virus RNA dimerization and core-RNA interactions. Nucleic Acids Res (2006) 0.99
Peptidyl-prolyl isomerase Pin1 is a cellular factor required for hepatitis C virus propagation. J Virol (2011) 0.98
A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol (2011) 0.96
Ubiquitin-independent proteasomal degradation during oncogenic viral infections. Biochim Biophys Acta (2011) 0.96
HCV and lymphoproliferation. Clin Dev Immunol (2012) 0.96
Core protein domains involved in hepatitis C virus-like particle assembly and budding at the endoplasmic reticulum membrane. Cell Microbiol (2006) 0.96
Hepatitis C virus core protein induces neuroimmune activation and potentiates Human Immunodeficiency Virus-1 neurotoxicity. PLoS One (2010) 0.96
Access of viral proteins to mitochondria via mitochondria-associated membranes. Rev Med Virol (2009) 0.95
In-vitro antiviral activity of Solanum nigrum against Hepatitis C Virus. Virol J (2011) 0.93
Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen. Genet Vaccines Ther (2009) 0.93
Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis. J Virol (2009) 0.92
Role of HCV Core gene of genotype 1a and 3a and host gene Cox-2 in HCV-induced pathogenesis. Virol J (2011) 0.92
Chronic hepatitis C and liver fibrosis. World J Gastroenterol (2014) 0.92
Modulation of mitogen-activated protein kinase-activated protein kinase 3 by hepatitis C virus core protein. J Virol (2013) 0.91
Potent inhibitors of hepatitis C core dimerization as new leads for anti-hepatitis C agents. Bioorg Med Chem Lett (2011) 0.89
Lucidone suppresses hepatitis C virus replication by Nrf2-mediated heme oxygenase-1 induction. Antimicrob Agents Chemother (2012) 0.89
NS4A protein as a marker of HCV history suggests that different HCV genotypes originally evolved from genotype 1b. Virol J (2011) 0.89
Kinetic analysis of the nucleic acid chaperone activity of the hepatitis C virus core protein. Nucleic Acids Res (2010) 0.89
Aqueous extract of the edible Gracilaria tenuistipitata inhibits hepatitis C viral replication via cyclooxygenase-2 suppression and reduces virus-induced inflammation. PLoS One (2013) 0.88
Inhibition of core gene of HCV 3a genotype using synthetic and vector derived siRNAs. Virol J (2010) 0.88
Enhanced Ca2+ leak from ER Ca2+ stores induced by hepatitis C NS5A protein. Biochem Biophys Res Commun (2008) 0.87
New small molecule inhibitors of hepatitis C virus. Bioorg Med Chem Lett (2009) 0.87
New therapeutic opportunities for hepatitis C based on small RNA. World J Gastroenterol (2007) 0.86
A time-resolved fluorescence-resonance energy transfer assay for identifying inhibitors of hepatitis C virus core dimerization. Assay Drug Dev Technol (2010) 0.85
Analysis of the RNA chaperoning activity of the hepatitis C virus core protein on the conserved 3'X region of the viral genome. Nucleic Acids Res (2011) 0.84
A disulfide-bonded dimer of the core protein of hepatitis C virus is important for virus-like particle production. J Virol (2010) 0.84
Core as a novel viral target for hepatitis C drugs. Viruses (2010) 0.83
Hepatitis C virus non-structural 5A abrogates signal transducer and activator of transcription-1 nuclear translocation induced by IFN-alpha through dephosphorylation. World J Gastroenterol (2007) 0.83
Association of laboratory parameters with viral factors in patients with hepatitis C. Virol J (2011) 0.83
Hepatitis C virus to hepatocellular carcinoma. Infect Agent Cancer (2012) 0.82
Effect of combined siRNA of HCV E2 gene and HCV receptors against HCV. Virol J (2011) 0.82
Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact. J Transl Med (2012) 0.82
Hemoglobin subunit beta interacts with the capsid protein and antagonizes the growth of classical swine fever virus. J Virol (2013) 0.82
Hepatitis C virus core protein enhances HIV-1 replication in human macrophages through TLR2, JNK, and MEK1/2-dependent upregulation of TNF-α and IL-6. FEBS Lett (2014) 0.81
Conventional protein kinase C inhibition prevents alpha interferon-mediated hepatitis C virus replicon clearance by impairing STAT activation. J Virol (2004) 0.81
HCV genotype-specific correlation with serum markers: higher predictability for genotype 4a. Virol J (2011) 0.80
HCV entry receptors as potential targets for siRNA-based inhibition of HCV. Genet Vaccines Ther (2011) 0.79
Identification of ionotrophic purinergic receptors in Huh-7 cells and their response towards structural proteins of HCV genotype 3a. Virol J (2011) 0.78
Nonstructural 5A Protein of Hepatitis C Virus Regulates Soluble Resistance-Related Calcium-Binding Protein Activity for Viral Propagation. J Virol (2015) 0.78
Down-regulation of IRES containing 5'UTR of HCV genotype 3a using siRNAs. Virol J (2011) 0.77
Anti-apoptotic effect of HCV core gene of genotype 3a in Huh-7 cell line. Virol J (2011) 0.77
Evaluation of canonical siRNA and Dicer substrate RNA for inhibition of hepatitis C virus genome replication--a comparative study. PLoS One (2015) 0.77
Virological Mechanisms in the Coinfection between HIV and HCV. Mediators Inflamm (2015) 0.77
Inhibition of hepatitis C virus using siRNA targeted to the virus and Hsp90. Cell Stress Chaperones (2016) 0.75
ADP-ribosylation Factor-related Protein 1 Interacts with NS5A and Regulates Hepatitis C Virus Propagation. Sci Rep (2016) 0.75
Development of persistent HCV genotype 3a infection cell culture model in huh-7 cell. Virol J (2012) 0.75
Inhibitory effect of kaolin minerals compound against hepatitis C virus in Huh-7 cell lines. BMC Res Notes (2014) 0.75
T-bet-mediated Tim-3 expression dampens monocyte function during chronic hepatitis C virus infection. Immunology (2016) 0.75
Hepatitis C Virus Nonstructural 5A Protein Interacts with Abelson Interactor 1 and Modulates Epidermal Growth Factor-mediated MEK/ERK Signaling Pathway. J Biol Chem (2016) 0.75
Saponin inhibits hepatitis C virus propagation by up-regulating suppressor of cytokine signaling 2. PLoS One (2012) 0.75
Abl Tyrosine Kinase Regulates Hepatitis C Virus Entry. Front Microbiol (2017) 0.75
Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol (2000) 5.26
Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol (2002) 4.55
Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature (1990) 4.10
Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A (1997) 3.88
Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med (1995) 3.41
Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol (1992) 3.35
Structure and cell cycle-regulated transcription of the human cyclin A gene. Proc Natl Acad Sci U S A (1994) 2.69
Cyclin A is required in S phase in normal epithelial cells. Biochem Biophys Res Commun (1992) 2.55
Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha. Ann Intern Med (2000) 2.43
State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases. Proc Natl Acad Sci U S A (1981) 2.37
Detection of hepatitis B virus sequences in serum by using in vitro enzymatic amplification. J Virol Methods (1988) 2.36
Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med (1985) 2.29
Delayed early embryonic lethality following disruption of the murine cyclin A2 gene. Nat Genet (1997) 2.01
Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology (1995) 2.00
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut (2000) 1.94
Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol (1998) 1.91
Hepatitis C in a ward for cystic fibrosis and diabetic patients: possible transmission by spring-loaded finger-stick devices for self-monitoring of capillary blood glucose. Infect Control Hosp Epidemiol (2001) 1.88
Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR-independent manner. Hepatology (2001) 1.84
Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. Hepatology (1998) 1.74
Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut (2005) 1.66
Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene (1999) 1.63
Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology (1999) 1.60
Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res (2001) 1.57
Epidemiological and virological analysis of couples infected with hepatitis C virus. Gut (1999) 1.55
Low prevalence of precore mutations in hepatitis B virus DNA in fulminant hepatitis type B in France. J Hepatol (1993) 1.49
Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest (1992) 1.45
Effect of pregnancy on chronic hepatitis C: a case-control study. Lancet (2000) 1.43
Defective hepatitis B virus particles are generated by packaging and reverse transcription of spliced viral RNAs in vivo. J Virol (1991) 1.41
Impact of TT virus infection in acute and chronic, viral- and non viral-related liver diseases. J Hepatol (2000) 1.40
Triggering of acute alcoholic hepatitis by alpha-interferon therapy. J Hepatol (1999) 1.39
The course of hepatitis C virus infection after liver transplantation. Hepatology (1994) 1.38
Evidence that hepatitis B virus has a role in liver-cell carcinoma in alcoholic liver disease. N Engl J Med (1982) 1.37
Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J Virol (2001) 1.36
Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology (1993) 1.36
A novel PCR technique using Alu-specific primers to identify unknown flanking sequences from the human genome. Genomics (1995) 1.30
A novel gene (HIP) activated in human primary liver cancer. Cancer Res (1992) 1.30
Liver resection and needle liver biopsy cause hematogenous dissemination of liver cells. Hepatology (1999) 1.28
Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging. Oncogene (2001) 1.26
Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology (1993) 1.26
Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J Natl Cancer Inst (2000) 1.23
Overexpression of human cyclin A advances entry into S phase. Oncogene (1995) 1.22
Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol (1999) 1.15
Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). J Gen Virol (1994) 1.15
Comparative analysis of two assays for genotyping hepatitis C virus based on genotype-specific primers or probes. J Hepatol (1995) 1.14
Frequent and early in utero HIV-1 infection. AIDS Res Hum Retroviruses (1991) 1.13
Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology (1997) 1.10
Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome. Oncogene (1998) 1.10
Modification of cyclin A expression by hepatitis B virus DNA integration in a hepatocellular carcinoma. Oncogene (1992) 1.10
Direct association and nuclear import of the hepatitis B virus X protein with the NF-kappaB inhibitor IkappaBalpha. Mol Cell Biol (1999) 1.09
Partial nucleotide sequence analysis of a French hepatitis C virus: implications for HCV genetic variability in the E2/NS1 protein. J Gen Virol (1991) 1.08
Immunohistochemical evidence for human immunodeficiency virus-1 infection of liver Kupffer cells. Hum Pathol (1990) 1.06
Efficiency of Ber-EP4 antibody for isolating circulating epithelial tumor cells before RT-PCR detection. Am J Clin Pathol (1999) 1.05
Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol (1999) 1.04
Structure and expression of the cyclin A gene in human primary liver cancer. Correlation with flow cytometric parameters. J Hepatol (1995) 1.04
Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. J Urol (2000) 1.03
Hepatitis C virus genotypes in French haemophiliacs: kinetics and reappraisal of mixed infections. J Med Virol (1997) 1.02
Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis (1999) 1.01
Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. J Hepatol (1997) 0.99
Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas. Int J Cancer (1999) 0.99
Permissiveness of human biliary epithelial cells to infection by hepatitis C virus. Hepatology (1999) 0.98
Detection of HIV1 RNA and p24 antigen in HIV1-infected human liver. Res Virol (1990) 0.98
Hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/PAP) is expressed and secreted by proliferating ductules as well as by hepatocarcinoma and cholangiocarcinoma cells. Am J Pathol (1999) 0.97
Hepatitis B virus DNA in Dane particles: evidence for the presence of replicative intermediates. J Infect Dis (1985) 0.97
Rearrangement of a common cellular DNA domain on chromosome 4 in human primary liver tumors. J Virol (1988) 0.97
MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis. J Hepatol (1993) 0.96
Hepatitis B virus DNA in mononuclear blood cells. A frequent event in hepatitis B surface antigen-positive and -negative patients with acute and chronic liver disease. J Hepatol (1986) 0.95
Spontaneous and iatrogenic spreading of liver-derived cells into peripheral blood of patients with primary liver cancer. Hepatology (1997) 0.95
HIP/PAP gene, encoding a C-type lectin overexpressed in primary liver cancer, is expressed in nervous system as well as in intestine and pancreas of the postimplantation mouse embryo. Am J Pathol (1999) 0.95
Gene transfer to hepatocellular carcinoma: transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors. Cancer Gene Ther (2000) 0.95
Dilated bile duct in patients receiving narcotic substitution: an early report. J Clin Gastroenterol (2000) 0.95
Crystallization and preliminary crystallographic study of HIP/PAP, a human C-lectin overexpressed in primary liver cancers. Acta Crystallogr D Biol Crystallogr (1999) 0.95
Circulating tumorous cells in patients with hepatocellular carcinoma. Clinical impact and future directions. Semin Cancer Biol (2000) 0.94
ATF/CREB site mediated transcriptional activation and p53 dependent repression of the cyclin A promoter. FEBS Lett (1996) 0.93
HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation (2000) 0.93
Development of a simple restriction fragment length polymorphism (RFLP) based assay for HCV genotyping and comparative analysis with genotyping and serotyping tests. J Virol Methods (1997) 0.92
Impact of medical recommendations on alcohol consumption in HCV positive patients. J Hepatol (2001) 0.92
Hepatitis B virus (HBV) and hepatocellular carcinoma. HBV DNA status and its implications. J Hepatol (1987) 0.91
Oncogenic activation of a human cyclin A2 targeted to the endoplasmic reticulum upon hepatitis B virus genome insertion. Oncogene (1998) 0.91
Inhibition of interferon-inducible MxA protein expression by hepatitis B virus capsid protein. J Gen Virol (1999) 0.91
Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ ganciclovir therapy of hepatocellular carcinoma: the woodchuck animal model. Cancer Gene Ther (2000) 0.91
Distinct effects of mitogens and the actin cytoskeleton on CREB and pocket protein phosphorylation control the extent and timing of cyclin A promoter activity. Mol Cell Biol (2001) 0.91
Loss of the G1-S control of cyclin A expression during tumoral progression of Chinese hamster lung fibroblasts. Cell Growth Differ (1993) 0.90
Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis (1998) 0.90
Comparison of a quantitative standardized HBV-DNA assay and a classical spot hybridization test in chronic active hepatitis B patients undergoing antiviral therapy. Res Virol (1989) 0.90
Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. Hepatology (1994) 0.90
In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum Gene Ther (1996) 0.89
Early development of mouse embryos null mutant for the cyclin A2 gene occurs in the absence of maternally derived cyclin A2 gene products. Dev Biol (2000) 0.89
High level of hepatitis C endemicity in Gabon, equatorial Africa. Trans R Soc Trop Med Hyg (1994) 0.89
Precore/core mutations of hepatitis B virus in hepatocellular carcinomas developed on noncirrhotic livers. Gastroenterology (1996) 0.89
Non-radioactive hepatitis B virus DNA probe for detection of HBV-DNA in serum. J Hepatol (1987) 0.89
Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients: significance and therapeutic implications. Kidney Int (1993) 0.89
Detection of hepatitis C virus (HCV) RNA sequences in liver tissue by in situ hybridization. J Hepatol (1992) 0.87
Nucleotide sequence analysis of three different hepatitis delta viruses isolated from a woodchuck and humans. J Gen Virol (1991) 0.86
Hepatitis B virus-related insertional mutagenesis implicates SERCA1 gene in the control of apoptosis. Oncogene (2000) 0.86
High expression of the human hepatocarcinoma-intestine-pancreas/pancreatic-associated protein (HIP/PAP) gene in the mammary gland of lactating transgenic mice. Secretion into the milk and purification of the HIP/PAP lectin. Eur J Biochem (2000) 0.86
Localization of insulin-like growth factor-II and hepatitis B virus mRNAs and proteins in human hepatocellular carcinomas. Lab Invest (1991) 0.85
Cyclin A: function and expression during cell proliferation. Prog Cell Cycle Res (1995) 0.85
Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects. Clin Infect Dis (1998) 0.85